Details of Disease

General Information of Disease (ID: DISPP65M)

• Disease Name: Escherichia coli infection
• Synonyms: INFECT ESCHERICHIA COLI; E coli Infections; E coli Infection; Colibacillosis; Escherichia coli infection; Infections, E coli; E Coli Infection; Escherichia Coli Infection; E COLI INFECT; E. coli Infection; Recurrent E. coli infections; Bacterial infection due to E. coli; E coli infections; Infection, E coli; Infection due to Escherichia coli; Infections, Escherichia coli; Infection, E. coli; Escherichia coli Infections; E coli infections, recurrent; Escherichia coli Infection; Infection, Escherichia coli; Bacterial infection caused by E. coli; INFECT E COLI; E. coli Infections; ESCHERICHIA COLI INFECT; Infection caused by Escherichia coli; E. coli infection; escherichia coli infection; e coli infection
• Disease Class: 1A03: Escherichia coli intestinal infection
• Definition: Infection with the organism Escherichia Coli.
• Disease Hierarchy:
  DIS5QJ9S: Bacterial infection
  DISEM33Q: Infectious disease
  DISPP65M: Escherichia coli infection
• ICD Code:
  ICD-11: ICD-11: 1A03
  ICD-10: ICD-10: A04, A04.4
• Disease Identifiers:
  MONDO ID: MONDO_0020920
  MESH ID: D004927
  UMLS CUI: C0014836
  MedGen ID: 4543
  HPO ID: HP:0002740
  SNOMED CT ID: 71057007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dukoral	DM7DNHK	Approved	NA	[1]

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Sitafloxacin	DMTV5XC	Phase 2/3	NA	[2]
ACE-527	DMMOUA8	Phase 2	NA	[3]
JNJ-63871860	DMU8N5X	Phase 2	NA	[4]
VAC52416	DMIJ2BG	Phase 1/2	Vaccine	[5]
Double mutant heat-labile toxin	DM696MT	Phase 1	NA	[6]
ETEC vaccine	DMSCD8Y	Phase 1	NA	[7]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Urtoxazumab	DMBJ8KG	Discontinued in Phase 2	Antibody	[8]
Enterotoxigenic E Coli vaccine	DM1JYAZ	Terminated	NA	[9]

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ACE-920	DMSUG3I	Investigative	NA	[10]
E coli EPVaccine	DMU95LH	Investigative	NA	[10]
RLP-035	DM07EVA	Investigative	NA	[10]
SBL-109	DM50FB0	Investigative	NA	[10]
SLP-0901	DM8BOB5	Investigative	NA	[10]
SLP-0907	DM6DTIR	Investigative	NA	[10]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 6 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BPI	TTXCSDR	Limited	Biomarker	[11]
NCF1	TTZ4JC3	Limited	Biomarker	[12]
TEP1	TTQGAVX	Limited	Biomarker	[13]
ABCB1	TT3OT40	Strong	Biomarker	[14]
NTRK2	TTKN7QR	Strong	ModifyingMutation	[15]
MCHR2	TTS17MG	Definitive	Genetic Variation	[16]

This Disease Is Related to 5 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
INTU	OTXB13E6	Limited	Altered Expression	[17]
STX2	OTO2IDDR	Limited	Biomarker	[18]
CCL4	OT6B8P25	Strong	Biomarker	[19]
MUC2	OT3X4QVX	Strong	Biomarker	[20]
PLB1	OTZ6TTYV	Definitive	Biomarker	[21]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] ClinicalTrials.gov (NCT02537847) Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli (SETAP). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT01060748) Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea. U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT03819049) A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health. U.S. National Institutes of Health.
• [6] Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli. Clin Vaccine Immunol. 2013 Nov;20(11):1764-70.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017547)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021716)
• [9] Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea. Cochrane Database Syst Rev. 2013 Jul 5;7:CD009029.
• [10] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [11] Protection of mice from lethal Escherichia coli infection by chimeric human bactericidal/permeability-increasing protein and immunoglobulin G1 Fc gene delivery.Antimicrob Agents Chemother. 2007 Feb;51(2):724-31. doi: 10.1128/AAC.00360-06. Epub 2006 Dec 4.
• [12] Genetic mutations potentially cause two novel NCF1 splice variants up-regulated in the mammary gland, blood and neutrophil of cows infected by Escherichia coli.Microbiol Res. 2015 May;174:24-32. doi: 10.1016/j.micres.2015.03.005. Epub 2015 Mar 17.
• [13] Complement-like proteins TEP1, TEP3 and TEP4 are positive regulators of periostial hemocyte aggregation in the mosquito Anopheles gambiae.Insect Biochem Mol Biol. 2019 Apr;107:1-9. doi: 10.1016/j.ibmb.2019.01.007. Epub 2019 Jan 25.
• [14] E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers.PLoS One. 2014 Jan 31;9(1):e87781. doi: 10.1371/journal.pone.0087781. eCollection 2014.
• [15] Aging and a peripheral immune challenge interact to reduce mature brain-derived neurotrophic factor and activation of TrkB, PLCgamma1, and ERK in hippocampal synaptoneurosomes.J Neurosci. 2011 Mar 16;31(11):4274-9. doi: 10.1523/JNEUROSCI.5818-10.2011.
• [16] Incomplete hemolytic-uremic syndrome in Argentinean children with bloody diarrhea.J Pediatr. 1995 Sep;127(3):364-7. doi: 10.1016/s0022-3476(95)70064-1.
• [17] Enteroaggregative Escherichia coli infection induces IL-8 production via activation of mitogen-activated protein kinases and the transcription factors NF-kappaB and AP-1 in INT-407 cells.Mol Cell Biochem. 2010 Apr;337(1-2):17-24. doi: 10.1007/s11010-009-0282-3. Epub 2009 Oct 24.
• [18] Cytotoxic effects of Shiga toxin-2 on human extravillous trophoblast cell lines.Reproduction. 2019 Mar;157(3):297-304. doi: 10.1530/REP-18-0581.
• [19] White matter damage and chemokine induction in developing rat brain after intrauterine infection.J Perinat Med. 2005;33(5):415-22. doi: 10.1515/JPM.2005.074.
• [20] Altered innate defenses in the neonatal gastrointestinal tract in response to colonization by neuropathogenic Escherichia coli.Infect Immun. 2013 Sep;81(9):3264-75. doi: 10.1128/IAI.00268-13. Epub 2013 Jun 24.
• [21] mRNA differential display of acute-phase proteins in experimental Escherichia coli infection.Electrophoresis. 2000 Aug;21(14):2957-68. doi: 10.1002/1522-2683(20000801)21:14<2957::AID-ELPS2957>3.0.CO;2-L.